Table 1.
Open drug intervention clinical trials in clinicaltrials.gov that include “circadian,” “clock,” or “chronobiology” as a keyword.
| Sponsor/Collaborators | Interventions | Conditions | Phase | NCT Number |
|---|---|---|---|---|
| University of Chicago | Drug: exenatide and Placebo | Type 2 diabetes; sleep disordered breathing | NP | NCT01136798 |
| Xinhua Hospital; Shanghai Jiao Tong University School of Medicine | Drug: etomidate; midazolam; propofol | Congenital hydronephrosis; congenital choledochal cyst; fracture | Phase 4 | NCT02013986 |
| Universitätsklinikum Hamburg-Eppendorf | Drug: Melatonin 2 mg and Placebo | Healthy night shift workers, sleep disorders | Phase 3 | NCT02108353 |
| Mount Sinai School of Medicine; National Institute of Mental Health (NIMH) | Drug: Modafinil and Placebo | Bipolar disorder | Phase 4 | NCT01965925 |
| Stanford University; Patient Centered Outcome Research Institute | Other: CONV care for the diagnosis and treatment of sleep disorders Other: PCCM for the diagnosis and treatment of sleep disorders | Obstructive sleep apnea of adult; insomnia; circadian rhythm sleep disorder, unspecified type; restless legs syndrome; narcolepsy and hypersomnia | NP | NCT02037438 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes of Health Clinical Center (CC) | Drug: brain dopamine reactivity methylphenidate; brain dopamine receptor C-11 raclopride | Cocaine abuse | Phase 0 | NCT02233829 |
| Rhode Island Hospital; The Depressive and Bipolar Disorder Alternative Treatment Foundation | Behavioral: triple chronotherapy; usual care | Depression; major depressive disorder; post-partum depression | NP | NCT02053649 |
| Hopital Foch | Drug: propofol; remifentanil | Anesthesia, general | Phase 3 | NCT00896714 |
| University of California, San Francisco; Masimo Labs | NP | Delirium; sleep disorders, circadian rhythm | NP | NCT01280097 |
| National Human Genome Research Institute (NHGRI); National Institutes of Health Clinical Center (CC) | Drug: dTR Melatonin (NIH CC PDS); melatonin CR Device: phototherapy (bright light) | Developmental delay disorders; chromosome deletion; mental retardation; sleep disorders, circadian rhythm; self-injurious behavior | Phase 1 | NCT00506259 |
| Oregon Health and Science University | Drug: melatonin Behavioral: regular sleep schedule; light | Insomnia; blindness; daytime sleepiness | NP | NCT00911053 |
| Hospital de Clinicas de Porto Alegre | Drug: melatonin and Placebo; amitriptyline and Placebo; melatonin and amitriptylin | Fibromyalgia | Phase 2 Phase 3 | NCT02041455 |
| Paracelsus Medical University; Technische Universität München | Drug: testosterone supplementation | Circadian; exercise; testosterone | NP | NCT02134470 |
| Sogo Rinsho Médéfi Co., Ltd.; Takeda | Drug: azilsartan; amlodipine | Hypertension | NP | NCT01762501 |
| Ann & Robert H Lurie Children's Hospital of Chicago; Children's Research Institute | Drug: prednisone and Placebo | Duchenne Muscular Dystrophy (DMD) | Phase 2 | NCT02036463 |
| Brigham and Women's Hospital | Biological: melatonin and Placebo | Delayed sleep phase disorder; jet-lag; shift-work disorder | NP | NCT00950885 |
| Oregon Health and Science University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Dietary supplement: melatonin Biological: melatonin | Blindness | NP | NCT00691444 |
| Prince of Songkla University | Device: selective laser trabeculoplasty Drug: travoprost | Intraocular pressure | Phase 4 | NCT02105311 |
| Neurim Pharmaceuticals Ltd. | Drug: circadin 2/5/10 mg and Placebo | Sleep disorders | Phase 3 | NCT01906866 |
| Hospices Civils de Lyon | Drug: melatonin and Placebo | Sleep disorders | Phase 2 | NCT01993251 |
| University of Vigo | Drug: aspirin | Type 2 diabetes | Phase 4 | NCT00725127 |
| University of Bergen | Drug: paracetamol and buprenorphine; paracetamol and Placebo; buprenorphine and Placebo | Depression; pain; dementia | Phase 4 | NCT02267057 |
| University of Pittsburgh; National Heart, Lung, and Blood Institute (NHLBI) | Behavioral: modified ME intervention; education only | Sleep apnea, obstructive | Phase 1 | NCT01377584 |
| Herlev Hospital | Drug: melatonin, N-acetyl-5-methoxytryptamine; isotonic saline, natrium chloride | Acute myocardial infarction; ischemia-reperfusion injury | Phase 2 | NCT01172171 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Smith-Magenis syndrome; circadian | Phase 2 | NCT02231008 |
| University of British Columbia | Drug: melatonin and Placebo | Delirium | Phase 4 | NCT02282241 |
| University of Michigan; University of Pennsylvania; Washington University Early Recognition Center | Drug: ISOFLURANE- experimental arm Other: control group: cognitive testing |
Post-operative cognitive dysfunction | NP | NCT01911195 |
| Haukeland University Hospital | Drug: Solu-Cortef; Cortef | Addison disease | Phase 1 Phase 2 | NCT02096510 |
| Charite University; Technische Universität München; University of Erlangen-Nürnberg Medical School; Praxis für Neurologie und Psychiatrie am Prinzregentenplatz, München; Technische Universität Berlin | Behavioral: patient centered structured support program | Mini-stroke | NP | NCT01586702 |
| Teva Pharmaceutical Industries; United BioSource Corporation | Drug: modafinil; armodafinil | Narcolepsy; obstructive sleep apnea; shift work sleep disorder | NP | NCT01792583 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Non-24-H sleep-wake disorder | Phase 3 | NCT01429116 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Non 24 H sleep wake disorder | Phase 3 | NCT01218789 |
| Aretaieion University Hospital; Baxter Healthcare Corporation | Procedure: maintenance with desflurane Procedure: maintenance with propofol |
Anesthesia; surgery; sleep disorders | NP | NCT02061514 |
| Endo Pharmaceuticals | Drug: morphine Sulfate 30 mg; Oxycodone 20 mg; Morphine 45 mg; Oxycodone 30 mg; Morphine sulfate 15 mg; Oxycodone 10 mg; morphine Sulfate 30 mg; Oxycodone 15 mg | Chronic around the clock opioid users | Phase 2 | NCT01871285 |
| Mundipharma Research GmbH & Co KG | Drug: Oxycodone/Naloxone prolonged release (OXN PR) tablets; oxycodone prolonged release (OxyPR) tablets | Pain|Constipation | Phase 3 | NCT01438567 |
| Brigham and Women's Hospital|National Center for Complementary and Integrative Health (NCCIH) | Drug: vitamin B12 | Sleep disorders, circadian rhythm | NCT00120484 | |
| Endo Pharmaceuticals|BioDelivery Sciences International | Drug: EN3409 | Low back pain|Osteoarthritis|Neuropathic pain | Phase 3 | NCT01755546 |
| Mundipharma Research GmbH & Co KG | Drug: Oxycodone; Naloxone | Malignant pain|Non-malignant pain | Phase 2|Phase 3 | NCT02321397 |
| Purdue Pharma LP | Drug: Oxycodone/Naloxone controlled-release; Placebo | Low back pain | Phase 3 | NCT01358526 |
| Janssen Pharmaceutical K.K. | Drug: tapentadol ER; morphine SR | Neoplasms | Phase 3 | NCT01309386 |
| Purdue Pharma LP | Drug: Oxycodone/Naloxone controlled-release; Oxycodone HCl controlled-release; Placebo | Low back pain | Phase 3 | NCT01427270 |
| Purdue Pharma LP | Drug: oxycodone/naloxone controlled-release; oxycodone HCl controlled-release; Placebo | Low back pain | Phase 3 | NCT01427283 |
| Oregon Health and Science University|Forest Laboratories | Drug: Placebo/escitalopram | Depression | NCT01214044 | |
| Technische Universität München|Cephalon | Drug: modafinil (Vigil); Placebo | Depression | Phase 2 | NCT00670813 |
| University of Copenhagen| Rigshospitalet, Denmark | Drug: erythropoietin (Epoetin-beta, NeoRecormon); erythropoietin (Epoetin-beta, NeoRecormon); Placebo | Renal effects | Phase 1 | NCT01584921 |
| Norwegian University of Science and Technology|St. Olavs Hospital|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|L'Hospitalet de Llobregat|University Hospital, Bonn|Cantonal Hospital of St. Gallen|Maastricht University Medical Center|Flinders University | Drug: intranasal fentanyl spray; slow release morphine | Cancer|Pain | Phase 3 | NCT01906073 |
| Endo Pharmaceuticals | Drug: oxymorphone IR | Chronic pain | Phase 3 | NCT01206907 |
| Mundipharma Research GmbH & Co KG | Drug: laxative | Opioid induced constipation | Phase 4 | NCT01957046 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Drug: haloperidol; Placebo; non-pharmacologic measures | Hypoactive delirium | Phase 3 | NCT02345902 |
| University of Oklahoma | Drug: memory XL; Placebo | Mild cognitive impairment | Phase 2 | NCT00903695 |
| University of Illinois at Chicago|Genentech, Inc. | Drug: ranibizumab (lucentis) | Glaucoma|New onset Glaucoma|Neovascular Glaucoma|New onset neovascular glaucoma | Phase 1|Phase 2 | NCT00727038 |
| Universitätsklinikum Hamburg-Eppendorf | Drug: melatonin 2 mg; Placebo | Healthy night shift workers, sleep disorders | Phase 3 | NCT02108353 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) | Drug: hydrocortisone; Placebo; hydrocortisone and melatonin; melatonin | Jet lag syndrome | Phase 2 | NCT00097474 |
| University of California, San Diego|California Breast Cancer Research Program | Device: light box (litebook) | Breast cancer | NCT00478257 | |
| St. Olavs Hospital | Drug: fentanyl | Chronic pain|Cancer | Phase 1|Phase 2 | NCT01248611 |
| National Heart, Lung, and Blood Institute (NHLBI) | Drug: melatonin; methylxanthine Device: light therapy | Sleep disorders, circadian rhythm | NCT00387179 | |
| Takeda | Drug: ramelteon; Placebo | Circadian dysregulation | Phase 4 | NCT00492011 |
| AstraZeneca | Drug: AZD1386; Placebo | Pain|Esophageal sensitivity | Phase 1 | NCT00711048 |
| Delray Medical Center | Drug: IV Ibuprofen | Pain | Phase 4 | NCT02152163 |
| Attikon Hospital | Drug: sugammadex; neostigmine/atropine | Post-operative cognitive dysfunction | NCT02419352 | |
| Mundipharma Research GmbH & Co KG | Drug: OXN PR followed by OxyPR tablets; OxyPR followed by OXN PR tablets | Severe chronic pain | Phase 2 | NCT01915147 |
| Greater Houston Retina Research | Drug: ranibizumab (lucentis) | Ischemic central retinal vein occlusion | Phase 1 | NCT00406471 |
| Pfizer | Drug: donepezil | Dementia, vascular|Dementia, mixed | Phase 3 | NCT00174382 |
| Pfizer | Drug: morphine sulfate extended release capsules | Pain | Phase 4 | NCT00640042 |
| Meander Medical Center|Dutch Kidney Foundation | Drug: melatonin tablet 3 mg once daily; Placebo comparator | Sleep Problems|Haemodialysis | Phase 3 | NCT00388661 |
| Meander Medical Center|Dutch Kidney Foundation | Drug: melatonin | Hemodialysis|Peritoneal dialysis|Sleep problems | Phase 3 | NCT00404456 |
| Ever Neuro Pharma GmbH|acromion GmbH|Geny Research Corp. | Drug: cerebrolysin; 0.9% saline solution | Vascular dementia | Phase 4 | NCT00947531 |
| Neovii Biotech | Drug: catumaxomab; prednisolone | Cancer|Neoplasms|Carcinoma|Malignant ascites | Phase 3 | NCT00822809 |
| Singapore General Hospital|Novartis|National Neuroscience Institute | Drug: exelon (rivastigmine); placebo | Cognitive impairment | Phase 4 | NCT00669344 |
| University of Toledo Health Science Campus | Drug: continuous release dopamine agonists | Parkinson disease | Phase 3 | NCT00465452 |
| Novartis | Drug: rivastigmine capsule; rivastigmine transdermal patch | Parkinson's disease dementia | Phase 3 | NCT00623103 |
| University of Rochester|Forest Laboratories | Drug: namenda | Delirium|Post-operative states | Phase 4 | NCT00303433 |
| INSYS Therapeutics Inc | Drug: fentanyl sublingual spray | Cancer|Pain | Phase 3 | NCT00538863 |
| Endo Pharmaceuticals|BioDelivery Sciences International | Drug: EN3409; Placebo | Low back pain | Phase 3 | NCT01633944 |
| Endo Pharmaceuticals|BioDelivery Sciences International | Drug: EN3409 | Low back pain | Phase 3 | NCT01675167 |
| Memorial Sloan Kettering Cancer Center | Drug: d-Methadone; Placebo | Pain|Bladder Cancer|Breast Cancer|CNS Cancer|Colon Cancer|Esophageal Cancer|Pancreatic Cancer|Prostate Cancer|Uterine Cancer|Head and neck Cancer|Eye Cancer|Otorhinolaryngologic neoplasms | Phase 1|Phase 2 | NCT00588640 |
| Neurim Pharmaceuticals Ltd. | Drug: melatonin (circadin); Placebo | Non-24 H sleep-wake disorder|Blindness | Phase 2 | NCT00972075 |
| National Eye Institute (NEI) | Drug: melatonin | Blindness | NCT00686907 | |
| Collegium Pharmaceutical, Inc. | Drug: oxycodone DETERx; Placebo | Chronic low back pain | Phase 3 | NCT01685684 |
| Cephalon|Teva Pharmaceutical Industries | Drug: ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) | Pain|Cancer|Sickle cell Anemia|Severe burns | Phase 2 | NCT00236093 |
| Shaare Zedek Medical Center | Drug: extended-release tramadol; paracetamol | Post-operative pain | NCT01024348 | |
| Cephalon|Teva Pharmaceutical Industries | Drug: ACTIQ | Cancer|Breakthrough pain | Phase 2 | NCT00236041 |
| Accera, Inc. | Drug: AC-1204; Placebo | Alzheimer's disease | Phase 2|Phase 3 | NCT01741194 |
| Mundipharma Pharmaceuticals B.V. | Drug: oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release | Pain | Phase 3 | NCT01167127 |
| Melissa Voigt Hansen|University of Copenhagen|Rigshospitalet, Denmark|Pharma Nord|Herlev Hospital | Drug: melatonin (N-acetyl-5-methoxytryptamine); Placebo | Breast cancer|Depression | Phase 2|Phase 3 | NCT01355523 |
| Mundipharma Pharmaceuticals B.V. | Drug: oxycodone and naloxone | Pain | Phase 3 | NCT01167699 |
| James Graham Brown Cancer Center|University of Louisville | Drug: Fentanyl Citrate Nasal Spray (FCNS) | Pain | Phase 4 | NCT01839552 |
| Kaplan Medical Center | Drug: oxycodone 10 mg | Elective laproscopic bilateral inguinal Hernia|Elective laproscopic cholecystectomy | Phase 4 | NCT00480142 |
| Brigham and Women's Hospital|Takeda | Drug: ramelteon; Placebo | Healthy | NCT00595075 | |
| Loma Linda University | Drug: morphine PCA started at the end of surgery, 1 Percocet 1/325 mg every 4 h; may receive a second Percocet if needed. For the 30 ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA | Post-op pain | NCT01939379 | |
| Vanda Pharmaceuticals | Drug: tasimelteon 20 mg capsule; tasimelteon 2 mg I.V. | Non-24-H-sleep-wake disorder | Phase 4 | NCT02130999 |
| Oregon Health and Science University | Drug: melatonin | Insomnia|Blindness|Daytime sleepiness | NCT00911053 | |
| Erasmus Medical Center|ZonMw: The Netherlands Organization for Health Research and Development | Drug: enalapril/hydrochlorothiazide; Placebo | Essential hypertension | Phase 4 | NCT02214498 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC) | Drug: brain dopamine reactivity; brain dopamine receptor | Cocaine abuse | Phase 0 | NCT02233829 |
| Boehringer Ingelheim | Drug: telmisartan; ramipril | Hypertension | Phase 4 | NCT00274612 |
| Ottawa Heart Institute Research Corporation|Schering-Plow|Medtronic | Drug: eptifibatide facilitated PCI | Myocardial infarction | Phase 3 | NCT00251823 |
| Boehringer Ingelheim | Drug: telmisartan combined with hydrochlorothiazide (80/12.5 mg); valsartan combined with hydrochlorothiazide (160/12.5 mg) | Hypertension|Diabetes mellitus, Type 2 | Phase 4 | NCT00239538 |
| US WorldMeds LLC|National Institute on Drug Abuse (NIDA) | Drug: lofexidine HCl | Renally impaired subjects | Phase 1 | NCT02313103 |
| University of Washington|Paul G. Allen Family Foundation | Drug: botox; normal saline | Painful bladder syndrome|Interstitial cystitis | Phase 4 | NCT00194610 |
| Children's Hospital of Philadelphia|Bayer|University of Pennsylvania | Drug: paracervical nerve block; sham paracervical block | Pain | Phase 4 | NCT02352714 |
| University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI) | Drug: losartan | Anemia, sickle cell|Sickle cell disease|Kidney disease|Hypertension| Proteinuria | Phase 2 | NCT02373241 |
| University of Alberta|Vancouver Coastal Health Research Institute | Drug: warfarin | Atrial fibrillation|Thrombus due to heart valve prosthesis|Deep venous thrombosis|Thromboembolism|DVT | Phase 4 | NCT02376803 |
| National Heart, Lung, and Blood Institute (NHLBI) | Drug: melatonin; methylxanthine| Procedure: light therapy | Sleep disorders, circadian rhythm | NCT00387179 | |
| Orphan Medical | Drug: sodium oxybate | Narcolepsy | Phase 3 | NCT00049803 |
| National Institute of Mental Health (NIMH) | Drug: low-dose sodium oxybate; high-dose sodium oxybate; low-dose zolpidem; high-dose zolpidem; Placebo | Sleep | NCT00777829 | |
| Massachusetts General Hospital | Drug: ramelteon; Placebo | Huntington's disease|Parkinson's disease|Dementia with lewy bodies|Sleep disorders|Circadian dysregulation | NCT00907595 | |
| Takeda | Drug: ramelteon; Placebo | Circadian dysregulation | Phase 4 | NCT00492011 |
| Massachusetts General Hospital | Drug: zolpidem CR; Placebo | Dementia|Alzheimer disease|Dementia, vascular|Sleep disorders|Circadian dysregulation | NCT00814502 | |
| Vanda Pharmaceuticals | Drug: tasimelteon; Placebo | Non-24-H sleep-wake disorder | Phase 3 | NCT01163032 |
| Vanda Pharmaceuticals | Drug: tasimelteon; Placebo | Non-24-H sleep-wake disorder | Phase 3 | NCT01430754 |
| Cephalon|Teva Pharmaceutical Industries | Drug: PROVIGIL 200 mg; armodafinil 250 mg; armodafinil 200 mg; armodafinil 150 mg; Placebo | Chronic shift work sleep disorder | Phase 3 | NCT00236080 |
| Child Psychopharmacology Institute | Drug: risperidone | Sleep disorders, circadian rhythm|Insomnia|psychomotor agitation | NCT00723580 | |
| Cephalon|Teva Pharmaceutical Industries | Drug: CEP-10953 (Armodafinil) | Narcolepsy|Sleep apnea, Obstructive|Sleep apnea Syndromes|Shift-work sleep disorder | Phase 3 | NCT00078312 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Smith-Magenis syndrome|Circadian | Phase 2 | NCT02231008 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Non-24-H sleep-wake disorder | Phase 3 | NCT01429116 |
| Takeda | Drug: ramelteon; Placebo | Sleep disorders, circadian rhythm | Phase 2 | NCT00593736 |
| Boehringer Ingelheim | Drug: pharmaton caplets; Placebo | Sleep disorders, circadian rhythm | Phase 2 | NCT02199847 |
| Sheba Medical Center | Drug: melatonin | Delayed sleep phase syndrome | Phase 1 | NCT00282061 |
| Cephalon|Teva Pharmaceutical Industries | Drug: armodafinil 150 mg/day; Placebo | Excessive sleepiness|Shift work sleep disorder | Phase 3 | NCT00080288 |
| National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC) | Drug: dTR melatonin (NIH CC PDS); melatonin CR Device: phototherapy (bright light) | Developmental delay disorders|Chromosome deletion|Mental retardation|Sleep disorders, circadian rhythm|Self injurious behavior | Phase 1 | NCT00506259 |
| Brigham and Women's Hospital|Sunovion|Massachusetts General Hospital | Drug: eszopiclone; matching Placebo | Shift-work sleep disorder | NCT00900159 | |
| Vanda Pharmaceuticals | Drug: tasimelteon 20 mg capsule; tasimelteon 2 mg I.V. | Non-24-H-sleep-wake disorder | Phase 4 | NCT02130999 |
| Neurim Pharmaceuticals Ltd. | Drug: melatonin (circadin); Placebo | Non-24 H sleep-wake disorder|blindness | Phase 2 | NCT00972075 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) | Drug: hydrocortisone; Placebo; hydrocortisone and melatonin; melatonin | Jet lag syndrome | Phase 2 | NCT00097474 |
| Teva Pharmaceutical Industries|United BioSource Corporation | Drug: modafinil/armodafinil | Narcolepsy|Obstructive sleep apnea|Shift work sleep disorder | NCT01792583 | |
| Vanda Pharmaceuticals | Drug: VEC-162 | Circadian rhythm sleep disorders | Phase 2 | NCT00490945 |
| Vanda Pharmaceuticals | Drug: tasimelteon | Non 24 H sleep wake disorder | Phase 3 | NCT01218789 |
| Cephalon|Teva Pharmaceutical Industries | Drug: armodafinil 100–250 mg/day | Excessive daytime sleepiness|Narcolepsy|Obstructive sleep apnea/hypopnea syndrome|Chronic shift work sleep disorder | Phase 3 | NCT00228553 |
| Brigham and Women's Hospital|National Center for Complementary and Integrative Health (NCCIH) | Drug: vitamin B12 | Sleep disorders, circadian rhythm | NCT00120484 |